Skip to main content
. 2022 Dec 26;14(4):e00560. doi: 10.14309/ctg.0000000000000560

Figure 5.

Figure 5.

IL17a levels in serum from patients with UC treated with 25, 50, or 100 mg ABX464 daily or placebo for 8 weeks. A total of 1,185 serum samples (500 μL of serum per sample) from 254 patients who received either ABX464 (25, 50, or 100 mg) or placebo were assessed during 5 visits (day 1, weeks 1, 4, 8, and 16) of the phase 2b trial (10). ****P < 0.0001 vs placebo. #P < 0.01 for 25, 50, and 100 mg daily; $P < 0.01 for 25 and 50 mg daily. QD, every day (quaque die); UC, ulcerative colitis.